Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Immunotherapy. 2013 May;5(5):489-95. doi: 10.2217/imt.13.36.
Conventional imaging is suboptimal at evaluating disease status in renal cell carcinoma (RCC) because of poor sensitivity. Furthermore, there is an unmet need for the treatment of metastatic RCC, both in terms of improvement of progression-free survival and limitation of toxicity. For this reason, radionuclide imaging and radionuclide therapy are extensively investigated. This review provides an overview of the current progress in molecular imaging and radionuclide therapy in clear cell RCC and will focus on promising detection and therapy strategies targeting the carbonic anhydrase IX antigen, which is expressed in clear cell RCC.
常规影像学在评估肾细胞癌 (RCC) 的疾病状态方面效果不佳，因为其敏感性较差。此外，转移性 RCC 的治疗也存在未满足的需求，需要提高无进展生存期并限制毒性。出于这个原因，放射性核素成像和放射性核素治疗得到了广泛的研究。本文综述了目前在透明细胞 RCC 中分子成像和放射性核素治疗的研究进展，并将重点介绍针对透明细胞 RCC 中表达的碳酸酐酶 IX 抗原的有前途的检测和治疗策略。
